GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Debt-to-EBITDA

ProSomnus (ProSomnus) Debt-to-EBITDA : -1.92 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProSomnus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.54 Mil. ProSomnus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $37.83 Mil. ProSomnus's annualized EBITDA for the quarter that ended in Dec. 2023 was $-21.55 Mil. ProSomnus's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.92.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ProSomnus's Debt-to-EBITDA or its related term are showing as below:

OSAPQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -55.05   Med: -6.04   Max: -2.33
Current: -2.43

During the past 4 years, the highest Debt-to-EBITDA Ratio of ProSomnus was -2.33. The lowest was -55.05. And the median was -6.04.

OSAPQ's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs OSAPQ: -2.43

ProSomnus Debt-to-EBITDA Historical Data

The historical data trend for ProSomnus's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Debt-to-EBITDA Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-2.86 -9.22 -55.05 -2.33

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 -1.69 4.40 -1.20 -1.92

Competitive Comparison of ProSomnus's Debt-to-EBITDA

For the Medical Devices subindustry, ProSomnus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProSomnus's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ProSomnus's Debt-to-EBITDA falls into.



ProSomnus Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProSomnus's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.538 + 37.831) / -17.735
=-2.33

ProSomnus's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.538 + 37.831) / -21.552
=-1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


ProSomnus  (OTCPK:OSAPQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ProSomnus Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ProSomnus's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ProSomnus (ProSomnus) Business Description

Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073